Informed analysis from internationally renowned contributors. They look at the post-2005 world and discuss how action may be taken to ensure that intellectual property regimes are interpreted and implemented in a manner supportive to the right to protect public health and, in particular, to promote access to medicines for all.
The introduction is available to download.
Part I. The Dynamics of Medicinal Patent Power
From Paris to Doha: The WTO Doha Declaration on the TRIPS Agreement and Public Health
The Cycle of Action and Reaction: Developments and Trends in Intellectual Property and Health
Ensuring Access to Medicines in 2005 and Beyond
Role, Perspectives and Challenges of the Generic Pharmaceutical Industry in Latin America
Market Concentration of the Transnational Pharmaceutical Industry and the Generic Industries: Trends on Mergers, Acquisitions and Other Transactions
Part II. Access Control: Beyond Patents to Data
Protecting Test Data for Pharmaceutical and Agrochemical Products under Free Trade Agreements
Intellectual Property, Data Exclusivity, Innovation and Market Access
The International Legal Status of Undisclosed Clinical Trial Data: From Private to Public Goods?
Data Protection: Options for Implementation
Part III. Ways Forward in Promoting Access
Advancing Public Health by Other Means: Using Competition Policy
Product Development Partnerships on 'Neglected Diseases': Intellectual Property and Improving Access to Pharmaceuticals for HIV/AIDS, Tuberculosis and Malaria
Creating and Promoting Domestic Drug Manufacturing Capacities: A Solution for Developing Countries?
Four Practical Measures to Enhance Access to Medical Technologies
Expanding Policy Options for Access to Medicines for All
The price of AIDS drugs was the issue that catapulted the importance of the patent regime upon our lives into the media. It led to massive campaigns about the impact of new global rules on patents, introduced through one of the agreements - that on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) - in the World Trade Organisation.
There were public protests, notably in the US and South Africa, awareness campaigns by many civil society organisations and pressures from many governments in the South to ensure these new rules did not limit access to AIDS and other drugs.
A brief overview of the issues is in this briefing (click here to download pdf):